Gilead Reports meta-analysis Data for Zanubrutinib in Meningioma

Gilead today announced meta-analysis results for Zanubrutinib in patients with Meningioma. The study demonstrated that Zanubrutinib reduces exacerbation rates significantly compared to standard of care or placebo. These results provide important insights into the treatment of Meningioma and support the continued development of Zanubrutinib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Zanubrutinib was consistent with previous observations, with no new safety signals identified.